Artiva Biotherapeutics, Inc.
ARTVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Artiva Biotherapeutics, Inc. (ARTV) is listed under Biotechnology. The $300.7M market capitalization puts ARTV squarely in small-cap range for its industry. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Market Cap
$300.7M
Beta
2.41
P/E (TTM)
—
P/E (Fwd)
-2.36
EPS (TTM)
$-3.21
EPS (Fwd)
$-2.61
ROE
-36.6%
ROA
-22.3%
Cash
$349.4M
Total Debt
$9.8M
Free CF
-$44.4M
52W Change
13.7%
Annual Financials
Cash vs Debt
Where ARTV stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ARTV finished 34.92% below its 150-day moving average ($9.05) and 26.28% below its 200-day moving average ($7.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARTV overbought or oversold?
At the October 20, 2026 close, ARTV's RSI(14) was 30.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Artiva Biotherapeutics, Inc. holds $349.4M in cash against $9.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$44.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -36.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $4.9M (2022) to $0 (2025), a 100% decline worth watching.
Artiva Biotherapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, ARTV has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Artiva Biotherapeutics, Inc. and its sector.